ADDED
As of February 24, 2026, the registrant had 137,649,352 outstanding ordinary shares.
Exhibits and Financial Statement Schedules 126 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections.
Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for: Access : Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.
Value : Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.
Reliability : Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.
In Europe, our portfolio consists primarily of brands, including Compeed , e llaOne , Solpadeine , Jungle Formula , and ACO .
Two key initiatives have been fundamental in advancing our self-care strategy our Supply Chain Reinvention Program, a global supply chain efficiency program, and Project Energize, a global investment and efficiency program.
Perrigo s unique complementary businesses enable each individually to play a specific reinforcing role, where 1) store brands generate cash for investments into the Company s key higher margin, higher growth brands, 2) branding and innovation capabilities deliver both brand and store brand demand generation designed to lead to stronger customer partnerships, 3) consumer-led innovation scaled across brands, store brands and geographies, and 4) leveraging global supply chain scale of more molecules at more price points to more consumers driving household penetration.
4 Perrigo Company plc - Item 1 Business Strategy Competitive Advantage Our objective is to grow our business by responsibly leveraging our global infrastructure to deliver high quality self-care solutions to customers and consumers through our expansive product offerings, providing new innovative products, brands, and product line extensions to consumers through entering new adjacent products and categories, new geographies and new channels of distribution organically and inorganically.
REMOVED
As of February 21, 2025, the registrant had 136,458,620 outstanding ordinary shares.
The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.
In Europe, our portfolio consists primarily of brands, including Compeed , EllaOne , Solpadeine , and ACO .
Two key initiatives are fundamental to advancing our self-care strategy our Supply Chain Reinvention Program, a global supply chain efficiency program, and Project Energize, a global investment and efficiency program.
Strategy Competitive Advantage Our objective is to grow our business by responsibly leveraging our global infrastructure to deliver high quality self-care solutions to customers and consumers through our expansive product offerings, providing new innovative products, brands, and product line extensions to existing consumers and servicing new consumers through entering new adjacent products and categories, new geographies and new channels of distribution organically and inorganically.
SEGMENTS Our reporting and operating segments reflect the way our chief operating decision maker, who is our CEO, makes operating decisions, allocates resources and manages the growth and profitability of the Company.
We previously had an Rx segment comprised of our generic prescription pharmaceuticals business in the U.S.
We additionally have a select lineup of branded self-care products.
The retailer, therefore, can price a store brand product below the competing national brand product and realize a greater percentage and dollar profit, while consumers benefit from receiving a high-quality product at a price below the comparable national brand product.
In March 2024, we launched Opill , the first ever FDA approved birth control pill for OTC use without age restriction.